Key takeaways
- MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene, described by a University of Southern California group in 2015.
- Studies that gave MOTS-c were in mice and cells; human studies so far measured natural levels, for example after exercise.
- A placebo-controlled phase 2a trial began in February 2026 and has no results.
- FDA says it has no human exposure data for MOTS-c; HHS cites a trial of an unnamed analogue that reported no serious adverse events.
- WADA names it in class S4.4.1, prohibited at all times.
01MOTS-c at a glance
The short version, dated 18 November 2026. Every line is sourced at the end of the page.
| Question | MOTS-c |
|---|---|
| What it is | A 16-amino-acid peptide, MRWQEMGYIFYPRKLR, encoded by a short open reading frame inside the mitochondrial 12S rRNA gene. Described in 2015. |
| Other names | Mitochondrial open reading frame of the 12S rRNA-c, the source of the name. Written “MOTs-C” on FDA’s compounding page. A mitochondrial-derived peptide, like humanin. |
| Evidence tier | T3 (mouse) and T4 (cell) for studies that gave it. T2 for human studies that measured the body’s own levels. |
| Human studies | None published that gave MOTS-c itself to people (PubMed and ClinicalTrials.gov, 18 Nov 2026). One registered: phase 2a, randomised, placebo-controlled, estimated n=120, recruiting, no results. |
| United States | Not FDA-approved. In FDA’s compounding Category 2 from 29 Sep 2023 to 22 Apr 2026, now listed as a nomination withdrawn. Named in HHS’s draft enforcement-discretion policy for licensed compounders (Federal Register notice, 30 Oct 2026), which is not binding and not an approval. |
| United Kingdom | No UK-licensed medicine found on the emc database (18 Nov 2026). |
| Australia | Not named in the Poisons Standard October 2026 (text searched 18 Nov 2026); we found no TGA statement applying any of its group entries to it and draw no scheduling conclusion of our own. |
| WADA | Prohibited at all times, class S4.4.1, metabolic modulators, named among activators of AMPK (2026 and 2027 Lists). |
02What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene. Most of the body’s proteins are encoded in the cell nucleus. Mitochondria, the compartments that produce most of a cell’s energy, carry their own small genome. In 2015, a group at the University of Southern California reported a short open reading frame inside the mitochondrial 12S rRNA gene that encodes a 16-amino-acid peptide, and named it MOTS-c.
In cell and mouse work, the same paper proposed skeletal muscle as its main target and a mechanism that runs through folate metabolism to AMPK, an enzyme that senses a cell’s energy state (T4). The body makes MOTS-c on its own, and it can be measured in blood and muscle. Our MOTS-c research overview covers the same studies in brief.
03How has MOTS-c been studied, and in what models?
Studies that gave MOTS-c were in mice and cells; human studies so far measured natural levels, for example after exercise.
Mice, 2015 (T3). The paper that described MOTS-c gave it to mice on a high-fat diet and to ageing mice, and measured insulin resistance and weight gain. The authors reported less insulin resistance in both groups, and less weight gain on the high-fat diet, in mice given MOTS-c. These are mouse results; the abstract does not give the number of animals.
Mice of different ages, 2021 (T3). The same group reported that MOTS-c increased measures of physical capacity in young, middle-aged and old mice. In the same paper, exercise raised the body’s own MOTS-c in human muscle and blood. Two authors declared consulting roles and shares in CohBar, Inc.
People: natural levels (T2). Human studies so far measured MOTS-c the body makes, for example before and after exercise. Studies like these show when levels change, not what giving MOTS-c does.
People: the first trial (registered). NCT07505745 is a phase 2a, randomised, placebo-controlled trial planned for 120 adults with prediabetes and overweight or obesity. Its primary outcomes are an insulin-sensitivity index from a glucose-tolerance test, and adverse events. It began in February 2026 and is recruiting, with no results.
An analogue. HHS’s 2026 policy appendix cites “a randomized placebo-controlled trial of a MOTS-c analogue” that “reported no serious adverse events”. The appendix does not name the analogue or the trial, and an analogue is a different molecule. FDA staff, reviewing MOTS-c for the July 2026 advisory committee, found no clinical studies or human exposure data for MOTS-c itself.
04What have regulators said about MOTS-c safety?
We found no controlled human safety study of MOTS-c itself (18 Nov 2026), and neither of the regulator statements below contains one.
FDA. FDA’s compounding page says MOTS-c products “may pose significant risk for immunogenicity for certain routes of administration”, that FDA “has not identified any human exposure data” for MOTS-c by any route, and that it lacks information on “whether it would cause harm if administered to humans”. FDA staff found no reports in FAERS, its adverse-event database, through 9 March 2025, and concluded that “potential safety risks associated with the use of MOTS-c in humans are unknown”. They also found no nonclinical toxicity studies of MOTS-c, and a laboratory study reporting that it is quickly broken down in human blood.
HHS. HHS read the record differently. Its appendix says “the available safety evidence points in one direction”, citing the analogue trial and rodent studies that, it says, showed no systemic toxicity.
How to read safety claims like these: side effects, documented vs unknown.
05Is MOTS-c an approved medicine? Status by country
United States. MOTS-c is not an FDA-approved drug. HHS records that it sat in FDA’s compounding Category 2 from 29 September 2023 to 22 April 2026, that FDA staff recommended against adding it to the 503A bulks list, and that the July 2026 advisory committee voted in favour. HHS then named MOTS-c among six peptides in a policy saying it does not intend to pursue enforcement against state-licensed pharmacies, federal facilities and licensed physicians compounding with them, under conditions that include a patient-specific prescription. The Federal Register notice of 30 October 2026 calls it a draft that “is not binding”. It is not an approval. Background: the July 2026 vote and the HHS policy.
United Kingdom. A search of the emc medicines database for MOTS-c returned no results on 18 November 2026. FDA’s 2026 briefing found no MOTS-c product authorised by the European Medicines Agency.
Australia. MOTS-c is not named in the Poisons Standard October 2026, and we found no TGA statement applying any of its group entries to it; we draw no scheduling conclusion of our own. Other Australian rules on unapproved peptide products are covered in are peptides legal in Australia?
Sport. WADA names MOTS-c in class S4.4.1, metabolic modulators, among activators of AMPK. It is prohibited at all times in the 2026 List and in the 2027 List, in force from 1 January 2027. See peptides and anti-doping.
06What doesn’t MOTS-c research show?
- Any effect of giving MOTS-c to people. No such study has published results; the first placebo-controlled trial is recruiting.
- That the mouse results apply to people. They have not been tested in a completed human trial.
- What natural MOTS-c levels mean for health. Level studies show changes and associations, not cause and effect.
- That the two best-known mouse studies are independent of commercial interest. Both come from the group that discovered MOTS-c; in 2021, two of its members declared consulting roles and shares in CohBar, Inc.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.